• Please log in or register to access this feature.

Editorial

You have full text access to this OnlineOpen article

Will targeting B cells be the answer for Sjögren's syndrome?

  1. R. John Looney†,*

Article first published online: 27 APR 2007

DOI: 10.1002/art.22604

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 5, pages 1371–1377, May 2007

Additional Information

How to Cite

Looney, R. J. (2007), Will targeting B cells be the answer for Sjögren's syndrome?. Arthritis & Rheumatism, 56: 1371–1377. doi: 10.1002/art.22604

Author Information

  1. University of Rochester, Rochester, New York

  1. †

    Dr. Looney has been an adviser to the following companies on the use of biologics in systemic lupus erythematosus, for which he has received consulting fees (less than $10,000 each), and he participates in multicenter clinical trials sponsored by several of these companies: Genentech, Biogen Idec, Roche, Amgen, Wyeth, Trubion, Coley, and MedImmune.

*Professor of Medicine, Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642

  1. †

    Dr. Looney has been an adviser to the following companies on the use of biologics in systemic lupus erythematosus, for which he has received consulting fees (less than $10,000 each), and he participates in multicenter clinical trials sponsored by several of these companies: Genentech, Biogen Idec, Roche, Amgen, Wyeth, Trubion, Coley, and MedImmune.

Publication History

  1. Issue published online: 27 APR 2007
  2. Article first published online: 27 APR 2007
  3. Manuscript Accepted: 14 FEB 2007
  4. Manuscript Received: 23 JAN 2007

Funded by

  • Autoimmunity Centers of Excellence award from the NIH. Grant Number: AI-056390

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (78K)

REFERENCES

  • 1
    Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms [review]. Arthritis Rheum 2006; 54: 2356–67.
    Direct Link:
  • 2
    Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 2006; 66: 625–39.
  • 3
    Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 20–7.
  • 4
    Cohen SB. Updates from B cell trials: efficacy. J Rheumatol Suppl 2006; 77: 12–7.
  • 5
    Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases [review]. Nat Rev Immunol 2006; 6: 394–403.
  • 6
    Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dorner T, Graninger WB, Brezinschek RI. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes. Wien Med Wochenschr 2006; 156: 61–7.
  • 7
    Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol 2001; 167: 3610–8.
  • 8
    Hansen A, Gosemann M, Pruss A, Reiter K, Ruzickova S, Lipsky PE, et al. Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 1897–908.
    Direct Link:
  • 9
    Fox RI. Sjögren's syndrome [review]. Lancet 2005; 366: 321–31.
  • 10
    Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjögren's syndrome (autoimmune epitheliitis). Lupus 2006; 15: 255–61.
  • 11
    Nagaraju K, Cox A, Casciola-Rosen L, Rosen A. Novel fragments of the Sjögren's syndrome autoantigens α-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule–induced cell death. Arthritis Rheum 2001; 44: 2376–86.
    Direct Link:
  • 12
    Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome: translational research. J Lab Clin Med 2006; 148: 281–8.
  • 13
    Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185–95.
    Direct Link:
  • 14
    Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome [published erratum appears in Proc Natl Acad Sci U S A 2006;103:5242]. Proc Natl Acad Sci U S A 2006; 103: 2770–5.
  • 15
    Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 2006; 54: 1165–73.
    Direct Link:
  • 16
    Cha S, Singson E, Cornelius J, Yagna JP, Knot HJ, Peck AB. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjögren's syndrome-associated autoantibodies. J Rheumatol 2006; 33: 296–306.
  • 17
    Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? [review]. Arthritis Rheum 2005; 52: 2984–95.
    Direct Link:
  • 18
    Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003; 48: 3187–201.
    Direct Link:
  • 19
    Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J, et al. Ectopic expression of the B cell–attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center–like structures in Sjögren's syndrome. Arthritis Rheum 2001; 44: 2633–41.
    Direct Link:
  • 20
    Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol 2005; 62: 421–8.
    Direct Link:
  • 21
    Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034–44.
  • 22
    Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796–803.
  • 23
    Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51–60.
  • 24
    Pillemer SR. Lymphoma and other malignancies in primary Sjögren's syndrome. Ann Rheum Dis 2006; 65: 704–6.
  • 25
    Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337–44.
  • 26
    Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2006; 45: 1012–5.
  • 27
    Hansen A, Reiter K, Pruss A, Loddenkemper C, Kaufmann O, Jacobi AM, et al. Dissemination of a Sjögren's syndrome–associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum 2006; 54: 127–37.
    Direct Link:
  • 28
    Mariette X. Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001; 60: 1007–10.
  • 29
    De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, et al. Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur J Immunol 2002; 32: 903–10.
    Direct Link:
  • 30
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002; 46: 741–7.
    Direct Link:
  • 31
    Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000; 29: 296–304.
  • 32
    Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2005; 44: 89–94.
  • 33
    Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59–68.
  • 34
    Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003; 62: 168–71.
  • 35
    Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134–9.
  • 36
    Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243–65.
  • 37
    Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006; 176: 6405–10.
  • 38
    Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785–98.
  • 39
    Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441–53.
  • 40
    Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004; 202: 496–502.
    Direct Link:
  • 41
    Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005; 25: 189–201.
  • 42
    Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827–34.
  • 43
    Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101: 3818–26.
  • 44
    Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054–61.
  • 45
    Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjögren's syndrome with rituximab. Ann Rheum Dis 2005; 64: 1087–8.
  • 46
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913–20.
  • 47
    Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjögren's syndrome. Rheumatology (Oxford) 2004; 43: 1309–10.
  • 48
    Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 2004; 77: 363–5.
    Direct Link:
  • 49
    Mariette X. Treatment of oral dryness in Sjögren's syndrome. Revue de Medecine Interne 2004; 25: 287–93. In French.
  • 50
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740–50.
    Direct Link:
  • 51
    Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64: 958–60.
  • 52
    Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, Cervera R, Font J, on behalf of the SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus 2004; 13: 969–71.
  • 53
    Shih WJ, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjögren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002; 27: 142–3.
  • 54
    Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003; 49: 394–8.
    Direct Link:
  • 55
    Touma Z, Sayad J, Arayssi T. Successful treatment of Sjögren's syndrome with rituximab. Scand J Rheumatol 2006; 35: 323–5.
  • 56
    Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004; 43: 1050–3.
  • 57
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–8.
  • 58
    Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005; 32: 143–9.
  • 59
    Seror R, Sordet C, Gottenberg JE, Guillevin L, Masson C, Sibilia J, et al. Good tolerance and efficacy of rituximab on systemic features in 12 patients with primary Sjögren's syndrome [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S378.
  • 60
    Seror R, Gottenberg JE, Sordet C, Guillevin L, Hachulla E, Masson C, et al. Changes in serum BAFF level and B-cell biomarkers after rituximab therapy, and before clinical relapse, in patients treated for systemic complications of primary Sjögren's syndrome [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S312.
  • 61
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8: R129.
  • 62
    Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007; 56: 1464–77.
    Direct Link:
  • 63
    D'Arbonneau F, Pers JO, Devauchelle V, Pennec Y, Saraux A, Youinou P. BAFF-induced changes in B cell antigen receptor–containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006; 54: 115–26.
    Direct Link:
  • 64
    Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006; 54: 2280–8.
    Direct Link:
  • 65
    Pers JO, d'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? Arthritis Rheum 2005; 52: 2411–4.
    Direct Link:
  • 66
    Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612–22.
    Direct Link:
  • 67
    Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377–86.
    Direct Link:
  • 68
    Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139–45.
  • 69
    Anolik JH, Barnard J, Owen T, Kemshetti S, Looney RJ, Sanz I. Recovery of the peripheral blood memory B cell compartment after rituximab treatment in SLE is delayed and lags behind peripheral lymphoid tissue memory B cell reconstitution. Submitted for publication.
  • 70
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455–9.
    Direct Link:
  • 71
    Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817–26.
View Full Article (HTML) Get PDF (78K)